Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years.

Pope J, Bessette L, Jones N, Fallon L, Woolcott J, Gruben D, Crooks M, Gold D, Haraoui B.

Rheumatology (Oxford). 2019 Aug 13. pii: kez324. doi: 10.1093/rheumatology/kez324. [Epub ahead of print]

PMID:
31410469
2.

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.

Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Song IH.

Ann Rheum Dis. 2019 Jul 30. pii: annrheumdis-2019-215764. doi: 10.1136/annrheumdis-2019-215764. [Epub ahead of print]

3.

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial.

Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC.

Arthritis Rheumatol. 2019 Jul 9. doi: 10.1002/art.41032. [Epub ahead of print]

PMID:
31287230
4.

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.

Choquette D, Bessette L, Alemao E, Haraoui B, Postema R, Raynauld JP, Coupal L.

Arthritis Res Ther. 2019 Jun 6;21(1):138. doi: 10.1186/s13075-019-1917-8.

5.

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.

Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S.

Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.

PMID:
30955357
6.

Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression.

Beaudoin C, Moore L, Gagné M, Bessette L, Ste-Marie LG, Brown JP, Jean S.

Osteoporos Int. 2019 Apr;30(4):721-740. doi: 10.1007/s00198-019-04919-6. Epub 2019 Mar 14.

PMID:
30877348
7.

Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.

Bessette L, Haraoui B, Chow A, Fortin I, Dixit S, Khraishi M, Haaland D, Elmoufti S, Staelens F, Bogatyreva I, Syrotuik J, Shaikh S.

Ther Adv Musculoskelet Dis. 2019 Mar 5;11:1759720X19831151. doi: 10.1177/1759720X19831151. eCollection 2019.

8.

Clinical peripheral enthesitis in the DESIR prospective longitudinal axial spondyloarthritis cohort.

Nadon V, Moltó A, Etcheto A, Bessette L, Michou L, D'Agostino MA, Claudepierre P, Wendling D, Haraoui P, Dougados M.

Clin Exp Rheumatol. 2019 Jul-Aug;37(4):561-565. Epub 2018 Dec 19.

PMID:
30620273
9.

Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis.

Moura CS, Rahme E, Maksymowych WP, Abrahamowicz M, Bessette L, Bernatsky S.

Scand J Rheumatol. 2019 Mar;48(2):121-127. doi: 10.1080/03009742.2018.1470253. Epub 2018 Aug 16.

PMID:
30112959
10.

Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population.

Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie LG, Brown JP.

J Bone Miner Res. 2018 Nov;33(11):1956-1966. doi: 10.1002/jbmr.3526. Epub 2018 Jun 29.

PMID:
29924429
11.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS.

Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

PMID:
29908669
12.

Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study.

Marshall JK, Bessette L, Shear NH, Lebovic G, Glass J, Millson B, Gaetano T, Gazel S, Latour MG, Laliberté MC, Thorne JC.

Clin Ther. 2018 Jun;40(6):1024-1032. doi: 10.1016/j.clinthera.2018.04.017. Epub 2018 May 24.

13.

Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study.

Bessette L, Lebovic G, Millson B, Charland K, Donepudi K, Gaetano T, Remple V, Latour MG, Gazel S, Laliberté MC, Thorne C.

Rheumatol Ther. 2018 Jun;5(1):75-85. doi: 10.1007/s40744-018-0109-3. Epub 2018 Apr 9.

14.

Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study.

Marshall JK, Bessette L, Thorne C, Shear NH, Lebovic G, Gerega SK, Millson B, Oraichi D, Gaetano T, Gazel S, Latour MG, Laliberté MC.

Clin Ther. 2018 Mar;40(3):415-429.e6. doi: 10.1016/j.clinthera.2018.02.001. Epub 2018 Mar 6.

15.

Sharing Ongoing Care with Primary Care Physicians Opens Up Opportunity for Timelier and Earlier Care by Rheumatologists for Patients with New Inflammatory Polyarthritis.

Nguyen P, Julien AS, Bessette L, Fortin PR, Michou L.

J Rheumatol. 2018 Feb;45(2):266-273. doi: 10.3899/jrheum.170494. Epub 2017 Dec 1.

PMID:
29196381
16.

Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.

Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K.

BMJ Open. 2017 Sep 18;7(9):e015872. doi: 10.1136/bmjopen-2017-015872.

17.

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment.

Bessette L, Khraishi M, Kivitz AJ, Kaliyaperumal A, Grantab R, Poulin-Costello M, Isaila M, Collier D.

Rheumatol Ther. 2017 Dec;4(2):391-404. doi: 10.1007/s40744-017-0079-x. Epub 2017 Sep 12.

18.

Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.

Rahman P, Zummer M, Bessette L, Baer P, Haraoui B, Chow A, Kelsall J, Kapur S, Rampakakis E, Psaradellis E, Lehman AJ, Nantel F, Osborne B, Tkaczyk C.

BMJ Open. 2017 Aug 30;7(8):e016619. doi: 10.1136/bmjopen-2017-016619.

19.

Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study.

Jean S, Hudson M, Gamache P, Bessette L, Fortin PR, Boire G, Bernatsky S.

Clin Rheumatol. 2017 Dec;36(12):2667-2671. doi: 10.1007/s10067-017-3796-1. Epub 2017 Aug 21.

PMID:
28828712
20.

Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study.

Pelletier JP, Raynauld JP, Beaulieu AD, Bessette L, Morin F, de Brum-Fernandes AJ, Delorme P, Dorais M, Paiement P, Abram F, Martel-Pelletier J.

Arthritis Res Ther. 2016 Nov 3;18(1):256.

21.

Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study.

Machado MA, Bernatsky S, Bessette L, Nedjar H, Rahme E.

BMC Musculoskelet Disord. 2016 Jul 19;17:298. doi: 10.1186/s12891-016-1142-4.

22.

The current economic burden of illness of osteoporosis in Canada.

Hopkins RB, Burke N, Von Keyserlingk C, Leslie WD, Morin SN, Adachi JD, Papaioannou A, Bessette L, Brown JP, Pericleous L, Tarride J.

Osteoporos Int. 2016 Oct;27(10):3023-32. doi: 10.1007/s00198-016-3631-6. Epub 2016 May 11.

23.

Dr. Roubille, et al reply.

Roubille C, Richer V, Starnino T, McCourt C, McFARLANE A, Fleming P, Siu S, Kraft J, Lynde C, Pope JE, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

J Rheumatol. 2016 May;43(5):993-4. doi: 10.3899/jrheum.151347. No abstract available.

PMID:
27134278
24.

Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.

Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP.

Osteoporos Int. 2016 Sep;27(9):2835-2844. doi: 10.1007/s00198-016-3607-6. Epub 2016 Apr 27. Review.

PMID:
27120345
25.

Loss of health related quality of life following low-trauma fractures in the elderly.

Tarride JE, Burke N, Leslie WD, Morin SN, Adachi JD, Papaioannou A, Bessette L, Brown JP, Pericleous L, Muratov S, Hopkins RB.

BMC Geriatr. 2016 Apr 19;16:84. doi: 10.1186/s12877-016-0259-5.

26.

How to Attract Trainees, a Pan-Canadian Perspective: Phase 1 of the "Training the Rheumatologists of Tomorrow" Project.

Cividino A, Bakowsky V, Barr S, Bessette L, Hazel E, Khalidi N, Pope J, Robinson D, Shojania K, Yacyshyn E, Lohfeld L, Crawshaw D.

J Rheumatol. 2016 Apr;43(4):788-98. doi: 10.3899/jrheum.150314. Epub 2016 Mar 1.

PMID:
26932343
27.

The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery.

Widdifield J, Moura CS, Wang Y, Abrahamowicz M, Paterson JM, Huang A, Beauchamp ME, Boire G, Fortin PR, Bessette L, Bombardier C, Hanly JG, Feldman D, Bernatsky S; CAnadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM).

J Rheumatol. 2016 May;43(5):861-8. doi: 10.3899/jrheum.151156. Epub 2016 Feb 15.

PMID:
26879353
28.

Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis Severity.

Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Gulliver WP, Haraoui B, Bissonnette R.

J Cutan Med Surg. 2016 May;20(3):221-7. doi: 10.1177/1203475415616073. Epub 2015 Nov 9. Review.

PMID:
26553732
29.

Opioid Use and Risk of Nonvertebral Fractures in Adults With Rheumatoid Arthritis: A Nested Case-Control Study Using Administrative Databases.

Acurcio FA, Moura CS, Bernatsky S, Bessette L, Rahme E.

Arthritis Rheumatol. 2016 Jan;68(1):83-91. doi: 10.1002/art.39422.

30.

Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.

Moura CS, Abrahamowicz M, Beauchamp ME, Lacaille D, Wang Y, Boire G, Fortin PR, Bessette L, Bombardier C, Widdifield J, Hanly JG, Feldman D, Maksymowych W, Peschken C, Barnabe C, Edworthy S, Bernatsky S; CAN-AIM.

Arthritis Res Ther. 2015 Aug 3;17:197. doi: 10.1186/s13075-015-0713-3.

31.

Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

J Rheumatol. 2015 Oct;42(10):1767-80. doi: 10.3899/jrheum.141112. Epub 2015 Jul 15. Review.

32.

Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 May;74(5):e34. doi: 10.1136/annrheumdis-2015-207419. Epub 2015 Mar 9. No abstract available.

PMID:
25755140
33.

2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada.

Rohekar S, Chan J, Tse SM, Haroon N, Chandran V, Bessette L, Mosher D, Flanagan C, Keen KJ, Adams K, Mallinson M, Thorne C, Rahman P, Gladman DD, Inman RD.

J Rheumatol. 2015 Apr;42(4):654-64. doi: 10.3899/jrheum.141000. Epub 2015 Feb 15.

PMID:
25684770
34.

2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations.

Rohekar S, Chan J, Tse SM, Haroon N, Chandran V, Bessette L, Mosher D, Flanagan C, Keen KJ, Adams K, Mallinson M, Thorne C, Rahman P, Gladman DD, Inman RD.

J Rheumatol. 2015 Apr;42(4):665-81. doi: 10.3899/jrheum.141001. Epub 2015 Feb 15.

PMID:
25684768
35.

Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis.

Ikic A, Beaudoin C, Brown JP, Bessette L, Fortin PR, Michou L.

Joint Bone Spine. 2015 Oct;82(5):373-5. doi: 10.1016/j.jbspin.2014.12.005. Epub 2015 Jan 22. No abstract available.

PMID:
25619157
36.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5. Review.

37.

Rheumatoid arthritis prevalence in Quebec.

Bernatsky S, Dekis A, Hudson M, Pineau CA, Boire G, Fortin PR, Bessette L, Jean S, Chetaille AL, Belisle P, Bergeron L, Feldman DE, Joseph L.

BMC Res Notes. 2014 Dec 19;7:937. doi: 10.1186/1756-0500-7-937.

38.

The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study.

Roubille C, Raynauld JP, Abram F, Paiement P, Dorais M, Delorme P, Bessette L, Beaulieu AD, Martel-Pelletier J, Pelletier JP.

Arthritis Res Ther. 2014 Dec 14;16(6):507. doi: 10.1186/s13075-014-0507-z.

39.

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10. Review.

PMID:
25490866
40.

Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials.

Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Kraft J, Lynde C, Gulliver W, Keeling S, Dutz J, Pope JE.

Arthritis Care Res (Hoboken). 2015 May;67(6):754-64. doi: 10.1002/acr.22519. Review.

41.

Rates of non-vertebral osteoporotic fractures in rheumatoid arthritis and postfracture osteoporosis care in a period of evolving clinical practice guidelines.

Roussy JP, Bessette L, Bernatsky S, Rahme E, Lachaine J.

Calcif Tissue Int. 2014 Jul;95(1):8-18. doi: 10.1007/s00223-014-9856-5. Epub 2014 Apr 16.

PMID:
24736884
42.

Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS).

Moura C, Bernatsky S, Abrahamowicz M, Papaioannou A, Bessette L, Adachi J, Goltzman D, Prior J, Kreiger N, Towheed T, Leslie WD, Kaiser S, Ioannidis G, Pickard L, Fraser LA, Rahme E.

Osteoporos Int. 2014 May;25(5):1473-81. doi: 10.1007/s00198-014-2649-x. Epub 2014 Feb 25.

43.

The impact of educational interventions on modifiable risk factors for osteoporosis after a fragility fracture.

Beaudoin C, Bessette L, Jean S, Ste-Marie LG, Brown JP.

Osteoporos Int. 2014 Jul;25(7):1821-30. doi: 10.1007/s00198-014-2618-4. Epub 2014 Feb 12.

PMID:
24519745
44.

Rheumatoid arthritis pharmacotherapy and predictors of disease-modifying anti-rheumatic drug initiation in the early years of biologic use in Quebec, Canada.

Roussy JP, Bessette L, Rahme E, Bernatsky S, Légaré J, Lachaine J.

Rheumatol Int. 2013 Aug 20. [Epub ahead of print]

PMID:
23959574
45.

Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate.

Raynauld JP, Martel-Pelletier J, Dorais M, Haraoui B, Choquette D, Abram F, Beaulieu A, Bessette L, Morin F, Wildi LM, Pelletier JP.

Cartilage. 2013 Jul;4(3):219-26. doi: 10.1177/1947603513483547.

46.

Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.

Roussy JP, Bessette L, Bernatsky S, Rahme E, Lachaine J.

Osteoporos Int. 2013 Sep;24(9):2483-92. doi: 10.1007/s00198-013-2321-x. Epub 2013 Mar 16.

PMID:
23504029
47.

Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials.

Steiman AJ, Pope JE, Thiessen-Philbrook H, Li L, Barnabe C, Kalache F, Kung T, Bessette L, Flanagan C, Haraoui B, Hochman J, Leclercq S, Mosher D, Thorne C, Bykerk V.

Rheumatol Int. 2013 May;33(5):1105-20. doi: 10.1007/s00296-012-2619-6. Epub 2013 Jan 6. Review.

PMID:
23292213
48.

Direct medical resource utilization associated with osteoporosis-related nonvertebral fractures in postmenopausal women.

Jean S, Bessette L, Belzile EL, Davison KS, Candas B, Morin S, Dodin S, Brown JP.

J Bone Miner Res. 2013 Feb;28(2):360-71. doi: 10.1002/jbmr.1756.

49.

Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis.

Barnabe C, Bessette L, Flanagan C, Leclercq S, Steiman A, Kalache F, Kung T, Pope JE, Haraoui B, Hochman J, Mosher D, Thorne C, Bykerk V.

J Rheumatol. 2012 Jun;39(6):1221-30. doi: 10.3899/jrheum.111393. Epub 2012 Apr 15. Review.

PMID:
22505697
50.

Treating rheumatoid arthritis to target: a Canadian physician survey.

Haraoui B, Bensen W, Bessette L, Le Clercq S, Thorne C, Wade J.

J Rheumatol. 2012 May;39(5):949-53. doi: 10.3899/jrheum.111134. Epub 2012 Apr 1.

Supplemental Content

Loading ...
Support Center